Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Halozyme Therapeutics' (HALO) Price Target Raised to $21 at JMP
June 4, 2015 8:23 AM EDTJMP Securities maintained a Market Outperform rating on Halozyme Therapeutics (NASDAQ: HALO) and raised its price target to $21.00 (from $17.00).
For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $19.57 yesterday.
... MoreHalozyme Therapeutics (HALO) PT Lifted to $21 at Piper Jaffray on AbbVie Deal
June 3, 2015 1:23 PM EDTPiper Jaffray analyst Charles Duncan reiterated an Overweight rating and bumped his price target on Halozyme Therapeutics (NASDAQ: HALO) to $21.00 (from $19.00) after the company announced an Enhanze partnership with yet another large biopharma player, AbbVie.
Duncan commented, ". We're not too surprised given management's... More
Halozyme Therapeutics (HALO), AbbVie (ABBV) Enter Collaboration for ENHANZE Combinations
June 3, 2015 8:31 AM EDTHalozyme Therapeutics (NASDAQ: HALO) announced a global collaboration and license agreement with AbbVie (NYSE: ABBV) to develop and commercialize products combining proprietary AbbVie compounds with Halozyme's ENHANZE platform.
Under the terms of the agreement, Halozyme will receive an initial $23 million... More
